Clinical Trials
2 trialsNCT02420938 2016-12-06
Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00803374 2011-11-21
Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma
Bristol-Myers Squibb
Phase 1 Withdrawn